New study used intraoperative infusions of specified glucose in patients about to have surgery to remove the kidney cancer and to evaluate how the tumors use glucose. The findings of the study are published in the journal Cell Metabolism.
To halt the growth of cancer cells, you have to know what feeds them.
‘Novel test using glucose may help open up new possibilities for therapeutic intervention in kidney cancer patients.
Researchers at the nationally recognized Kidney Cancer Program at UT Southwestern's Harold C. Simmons Comprehensive Cancer Center have developed a novel approach using glucose that may open up new opportunities for therapeutic intervention.
Kidney cancer is one of the ten most prevalent malignancies in the world, and its frequency is increasing. According to UT Southwestern, the most common type, accounting for 70 percent of all kidney cancers, is clear cell renal cell carcinoma (ccRCC), a tumor characterized by the buildup of sugar and fat.
A team of investigators led by Dr. Kevin Courtney, Assistant Professor of Internal Medicine, and Dr. Elizabeth Maher, Professor of Internal Medicine and the Theodore H. Strauss Professor in Neuro-Oncology, used intraoperative infusions of labeled glucose in patients about to have surgery to remove the kidney cancer to assess how the tumors use glucose.
The study found that ccRCC tumors process glucose differently than most tissues. Rather than breaking glucose down completely through the tricarboxylic acid cycle to extract the maximum amount of energy, the tumor cells stopped short. This suggests that by avoiding the complete breakdown of glucose, cancer cells may have access to other building blocks to support their growth.
"Not long ago, most cancer biologists thought that glycolysis, the partial degradation of glucose to lactate, was an essential feature of aggressive tumors. This idea persisted for a century although it was based entirely on analyzing cancer cell metabolism outside of the body," said Dr. Ralph DeBerardinis, Professor at the Children's Medical Center Research Institute at UT Southwestern and a Howard Hughes Medical Institute Investigator.
"When we began to study metabolism directly in cancer patients, we realized that glycolysis was not a universal feature of aggressive tumors. The new findings in ccRCC demonstrate that some tumors do rely on glycolysis and that these isotope labeling techniques can identify tumors using very different kinds of metabolism," added Dr. DeBerardinis, the Joel B. Steinberg, M.D. Chair in Pediatrics and a Sowell Family Scholar in Medical Research.
The team found that ccRCC tumors are unique when compared with non-small cell lung cancers and glioblastoma (brain) tumors.
"To our knowledge, this is the first study to demonstrate stark differences in how ccRCC tumors in patients metabolize glucose relative to normal kidney tissue or other tumor types," Dr. Courtney said.
The results underscore the metabolic shift that occurs in ccRCC. "We are excited to continue these studies to find metabolic vulnerabilities in ccRCC that may pave the way to new treatments," said Divya Bezwada, co-first author of the study and a graduate student in the laboratory of Dr. DeBerardinis.
The UTSW team is supported in part by a Specialized Program of Research Excellence (SPORE) award from the National Cancer Institute, one of two such awards for kidney cancer in the country, and additional funding from the National Institutes of Health, the National Cancer Institute, the Cancer Prevention and Research Institute of Texas, the American Chemical Society, and the Howard Hughes Medical Institute.
"By applying a sensitive technique involving isotope-labeled tracers in patients, this team is poised to make important discoveries that reveal how kidney cancer cells grow," said Dr. James Brugarolas, Director of the Kidney Cancer Program and Professor of Internal Medicine, who holds the Sherry Wigley Crow Cancer Research Endowed Chair in Honor of Robert Lewis Kirby, M.D.